Ebola vaccine is used against viral hemorrhagic fever that is causes due to Ebola virus disease. This disease initially spread from animals to human and later transmission started from human to human. The Ebola virus disease is considered as life threatening disease and major way for this disease transfer is direct contact of infected person/animals body fluid.
However, there is no any drug available to cure this disease, only some preventive methods are followed, that help patient to improve health condition. Also, there are various Ebola vaccines market in development stage, that are expected to launch in market in the near future.
Increasing prevalence of Ebola across the globe is a major factor driving growth of the global Ebola vaccine market. As per the data published by World Health Organization (WHO), in January 2018, Ebola virus fatality rate is around 50%.
The global Ebola vaccine market has been segmented on the basis of virus strain and region. On the basis of virus strain, the global Ebola vaccine market has been segmented into Chimpanzee Adeno virus type 3-Zaire Ebola virus, Recombinant vesicular stomatitis virus-Zaire Ebola virus, and Adeno virus serotype 26- Zaire Ebola Virus.
Request Sample Copy of the Report: https://marketresearch.biz/report/ebola-vaccine-market/request-sample/
Regional segmentation includes North America, Europe, Latin America, Asia Pacific and Middle East & Africa. North America contributes major market share and expected to maintain its dominance over the forecast period owing to presence of leading players and high vaccine development rate in the region. Asia Pacific region is expected to witness rapid growth over the forecast period. Countries such as India, China are expected to support growth of the market, owing to increasing government initiative to spread awareness about the Ebola vaccine.
Some prominent players in the global Ebola vaccine market includes Sarepta Therapeutics Inc., Mapp Biopharmaceutical Inc., Regeneron Pharmaceuticals, Inc., Merck & Company, Inc., GlaxoSmithKline plc, Novavax Inc., and GeoVax Labs Inc.